Rapamycin Treatment Alleviates Chronic GVHD-Induced Lupus Nephritis in Mice by Recovering IL-2 Production and Regulatory T Cells While Inhibiting Effector T Cells Activation

• Published in: Biomedicines Vol. 11; no. 3; p. 949
• Main Authors: Zhang, Jilu, Wang, Xun, Wang, Renxi, Chen, Guojiang, Wang, Jing, Feng, Jiannan, Li, Yan, Yu, Zuyin, Xiao, He
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-03-2023; MDPI
• Subjects: Animal models; Antibodies; Apoptosis; Autoantibodies; CD25 antigen; CD4 antigen; Cell activation; Cell division; Cell growth; cGVHD; Chemokines; Effector cells; Flow cytometry; Foxp3 protein; Graft versus host disease; Graft-versus-host reaction; Health aspects; IL-2; Immunological tolerance; Immunoregulation; Immunosuppressive agents; Inflammation; Interleukin 10; Interleukin 2; Interleukin 4; Kinases; Laboratory animals; Lupus; Lupus nephritis; Lymphocytes; Lymphocytes T; mRNA; Nephritis; Proteins; Rapamycin; Renal function; Splenocytes; Systemic lupus erythematosus; T cells; Tregs; Urine; γ-Interferon; China; St Louis Missouri; United States > US; lupus nephritis; IL-2; cGVHD; Tregs; rapamycin
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines11030949

In this study, we test the therapeutic effects of rapamycin in a murine model of SLE-like experimental lupus nephritis induced by chronic graft-versus-host disease (cGVHD). Our results suggest that rapamycin treatment reduced autoantibody production, inhibited T lymphocyte and subsequent B cell activation, and reduced inflammatory cytokine and chemokine production, thereby protecting renal function and alleviating histological lupus nephritis by reducing the occurrence of albuminuria. To explore the potential mechanism of rapamycin's reduction of kidney damage in mice with lupus nephritis, a series of functional assays were conducted. As expected, rapamycin remarkably inhibited the lymphocytes' proliferation within the morbid mice. Interestingly, significantly increased proportions of peripheral CD4+FOXP3+ and CD4+CD25high T cells were observed in rapamycin-treated group animals, suggesting an up-regulation of regulatory T cells (Tregs) in the periphery by rapamycin treatment. Furthermore, consistent with the results regarding changes in mRNA abundance in kidney by real-time PCR analysis, intracellular cytokine staining demonstrated that rapamycin treatment remarkably diminished the secretion of Th1 and Th2 cytokines, including IFN-γ, IL-4 and IL-10, in splenocytes of the morbid mice. However, the production of IL-2 from splenocytes in rapamycin-treated mice was significantly higher than in the cells from control group animals. These findings suggest that rapamycin treatment might alleviate systemic lupus erythematosus (SLE)-like experimental lupus nephritis through the recovery of IL-2 production, which promotes the expansion of regulatory T cells while inhibiting effector T cell activation. Our studies demonstrated that, unlike other commonly used immunosuppressants, rapamycin does not appear to interfere with tolerance induction but permits the expansion and suppressive function of Tregs in vivo.